Results 181 to 190 of about 2,555,654 (307)

Integrating Asciminib into the Evolving Treatment Landscape of Chronic Myeloid Leukemia: A Canadian Perspective. [PDF]

J Blood Med
Kim DDH, Busque L, Hillis C, Laneuville P, Savoie ML.   +4 more
europepmc   +1 more source

Molecular Glue Degraders in Early Development for Cancer Therapy

Medicinal Research Reviews, EarlyView.
ABSTRACT Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein‐protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they ...
E. Sila Ozdemir, Hyunbum Jang, Ozlem Keskin, Attila Gursoy, Ruth Nussinov   +4 more
wiley   +1 more source

SHP2 in Cancer: From Tumor Biology to Therapeutic Targeting

Medicinal Research Reviews, EarlyView.
ABSTRACT SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA repair, angiogenesis ...
Maryam Jama, Michael Overduin, Khaled H. Barakat   +2 more
wiley   +1 more source

BCR-ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review. [PDF]

Health Sci Rep
Emeline Oloume M, Pieme A, Ngalle CK, Tapouli R, Tagny CT.   +4 more
europepmc   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review. [PDF]

Blood Res
Han JJ, Lee JO, Kim KH, Lee SE, Sohn SK, Jung CW, Kim H, Korean Society of Hematology Chronic Myeloid Leukemia Working Party.   +7 more
europepmc   +1 more source

Before Guillain‐Barre Syndrome Is Attributed to a CMV Infection, the Diagnosis Must Be Confirmed and Other Causes Must Be Ruled Out

The Kaohsiung Journal of Medical Sciences, EarlyView.
Josef Finsterer
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

, 2013
VIGNERI, PAOLO, Experts in Chronic Myeloid Leukemia including, Saglio, Giuseppe   +2 more
core   +1 more source

Correction: Target inhibition of CBP induced cell senescence in BCR-ABL- T315I mutant chronic myeloid leukemia. [PDF]

Front Oncol
Yang K, Wang F, Zhang H, Wang X, Chen L, Su X, Wu X, Han Q, Chen Z, Chen ZS, Fu L.   +10 more
europepmc   +1 more source